Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.48 |
| ▸ | PLK1 | P53350 | 3/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17196843 | 0.86 | EGFR (0.52) | EGFRPLK1LRRK2ALK | |
| SCHEMBL17196746 | 0.85 | EGFR (0.47) | EGFRPLK1 | |
| SCHEMBL17059310 | 0.83 | LRRK2 (0.49) | EGFRPLK1LRRK2ALKAURKA | |
| SCHEMBL18657453 | 0.78 | EGFR (0.69) | EGFRINSRIGF1R | |
| SCHEMBL18657398 | 0.78 | EGFR (0.69) | EGFRINSRIGF1R | |
| SCHEMBL17196873 | 0.77 | EGFR (0.55) | EGFRLRRK2ALK | |
| SCHEMBL24178981 | 0.77 | ALK (0.52) | EGFRPLK1ALKAURKAINSR | |
| SCHEMBL17059285 | 0.77 | EGFR (0.72) | EGFR | |
| SCHEMBL28728689 | 0.77 | EGFR (0.57) | EGFRPLK1LRRK2ALKAURKA | |
| SCHEMBL26528471 | 0.76 | ALK (0.64) | EGFRPLK1ALKAURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879008-B2 | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2018-01-30 | — | — | US | disclosed |
| EP-3144292-A1 | 2,3,4,6-TETRA-SUBSTITUTED BENZENE-1,5-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170057957-A1 | 2,3,4,6-TETRA-SUBSTITUTED BENZENE-1,5-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-03-02 | — | — | US | disclosed |
| US-20170057957-A1 | 2,3,4,6-TETRA-SUBSTITUTED BENZENE-1,5-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-03-02 | — | — | US | disclosed |
| WO-2015158233-A1 | 2,3,4,6-TETRA-SUBSTITUTED BENZENE-1,5-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | 上海海雁医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057957-A1 | 2,3,4,6-TETRA-SUBSTITUTED BENZENE-1,5-DIAMINE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | CYP4F11, CYP2D6, CYP4B1 | EGFR 3813/4885PLK1 3627/4885LRRK2 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.